Cilengitide TFA
Code | Size | Price |
---|
TAR-T6806-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6806-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
CAS:
199807-35-7
Molecular Weight:
702.68
Pathway:
Autophagy|Cytoskeletal Signaling
Purity:
0.98
SMILES:
OC(=O)C(F)(F)F.CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O
Target:
Autophagy|Integrin
References
Nisato RE, et al. Angiogenesis, 2003, 6(2), 105-119.
Oliveira-Ferrer L, et al. J Exp Clin Cancer Res, 2008, 27:86.
Reardon DA, et al. Genes Cancer, 2011, 2(12):1159-1165.